Zolmitriptan
zolmitriptan · Brand: Zomig, Zomig-ZMT
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Acute migraine with or without aura | Adults (≥18 years) | Acute abortive (oral tablet, ODT, nasal spray) | FDA Approved |
| Acute migraine with or without aura | Adolescents (12–17 years) | Acute abortive (nasal spray only) | FDA Approved |
Zolmitriptan was approved by the FDA in 1997 and is the only triptan available in three distinct formulations (conventional tablet, orally disintegrating tablet, and nasal spray). It is distinguished from first-generation sumatriptan by higher oral bioavailability (~40% vs ~15%), metabolism via CYP1A2 rather than MAO-A, and the formation of a pharmacologically active metabolite (N-desmethyl-zolmitriptan) that is 2–6 times more potent at 5-HT1B/1D receptors. The nasal spray formulation is the only zolmitriptan product approved for adolescents aged 12–17; oral tablets are approved for adults only. Zolmitriptan is not indicated for migraine prophylaxis or cluster headache treatment.
Menstrual migraine prophylaxis: Zolmitriptan 2.5 mg BID or TID given perimenstrually has shown efficacy in RCTs for short-term prevention; evidence quality is high (one of the triptans with best evidence for this use).
Cluster headache (nasal spray): Zolmitriptan 5–10 mg nasal spray has shown efficacy in episodic cluster headache in one RCT; evidence quality is moderate.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Migraine — standard oral treatment | 2.5 mg PO | 2.5 mg PO | 10 mg/24 h | May repeat ≥2 h if headache returns; 5 mg offers little added benefit over 2.5 mg 1.25 mg achievable by halving scored 2.5 mg tablet |
| Migraine — dose-sensitive patients | 1.25 mg PO | 1.25–2.5 mg PO | 10 mg/24 h | Break scored 2.5 mg tablet in half Appropriate for patients who experience AEs at 2.5 mg |
| Migraine — higher dose if 2.5 mg insufficient | 5 mg PO | 5 mg PO | 10 mg/24 h | Max single dose; more AEs than 2.5 mg with little additional efficacy Reserve for patients with documented non-response to 2.5 mg |
| Migraine — nausea prominent or rapid onset needed (nasal spray) | 5 mg IN | 2.5–5 mg IN | 10 mg/24 h | Spray into one nostril; may repeat ≥2 h Nasal spray is the only formulation approved for adolescents 12–17 |
| Migraine — co-prescribed with cimetidine | 2.5 mg PO | 2.5 mg PO | 5 mg/24 h | Cimetidine inhibits CYP1A2, increasing zolmitriptan and active metabolite levels Max single dose 2.5 mg |
Special Population Adjustments
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Moderate-to-severe hepatic impairment | 1.25 mg PO | 1.25 mg PO | 5 mg/24 h (severe) | AUC increases 3-fold; Cmax 1.5-fold; BP elevations reported in this group 7/27 patients with hepatic impairment had 20–80 mmHg BP elevations at 10 mg |
| Adolescent 12–17 years (nasal spray only) | 5 mg IN | 5 mg IN | 10 mg/24 h | Only nasal spray approved for this age group Oral tablets not approved for pediatric patients |
| Elderly patients | 1.25–2.5 mg PO | 2.5 mg PO | 10 mg/24 h | PK similar to younger adults; start low due to CV risk Cardiovascular evaluation before first dose recommended |
Unlike sumatriptan and rizatriptan, zolmitriptan produces a pharmacologically active metabolite (N-desmethyl-zolmitriptan) that is 2–6 times more potent at 5-HT1B/1D receptors than the parent compound. This metabolite achieves plasma concentrations approximately two-thirds those of zolmitriptan and has a similar half-life (~3 hours). Because the active metabolite extends the effective duration of receptor engagement, zolmitriptan may offer a theoretical advantage in reducing headache recurrence compared to triptans without active metabolites, though clinical evidence for this specific benefit is mixed.
Pharmacology
Mechanism of Action
Zolmitriptan is a selective agonist at serotonin 5-HT1B and 5-HT1D receptors, with moderate affinity for 5-HT1A subtypes. Its anti-migraine activity is mediated through cranial vasoconstriction via 5-HT1B receptors on meningeal arteries and inhibition of pro-inflammatory neuropeptide release (CGRP, substance P, VIP) from trigeminal perivascular nerve endings via 5-HT1D receptors. Zolmitriptan also has evidence of central activity, as it can penetrate the blood-brain barrier more effectively than sumatriptan due to its greater lipophilicity, potentially contributing to central inhibition of trigeminal pain transmission in the brainstem.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly absorbed; oral bioavailability ~40%; 75% of Cmax within 1 h; Tmax ~2 h (oral tablet); food does not affect bioavailability | Bioavailability ~3-fold higher than sumatriptan; AUC and Cmax reduced ~40% and ~25% during migraine attacks due to gastric stasis |
| Distribution | Vd 7.0 L/kg; protein binding ~25% | Moderate lipophilicity allows greater CNS penetration than sumatriptan; low binding means displacement interactions are unlikely |
| Metabolism | Hepatic via CYP1A2; 3 metabolites: N-desmethyl-zolmitriptan (active, 2–6x more potent, ~2/3 of metabolism), N-oxide and IAA (inactive, ~1/3) | CYP1A2 inhibitors (cimetidine) increase levels — dose reduction required; MAO-A inhibitors also increase exposure; selegiline (MAO-B) has no effect |
| Elimination | t½ ~3 h (parent and active metabolite); total clearance 31.5 mL/min/kg; ~1/6 renal clearance; renal tubular secretion | Active metabolite extends effective duration of action; hepatic impairment increases AUC 3-fold with significant BP risk |
Side Effects
Adverse reaction data reflect five pooled placebo-controlled trials in 2,074 adult patients (Studies 1–5). Incidence rates are from the FDA prescribing information Table 1. Several adverse reactions are dose-related, notably paresthesia, sensations of tightness in the chest/neck/jaw/throat, dizziness, somnolence, and possibly asthenia and nausea. In a long-term open-label study, 8% of 2,058 patients withdrew due to adverse reactions.
| Adverse Effect | Incidence (5 mg / Placebo) | Clinical Note |
|---|---|---|
| Pain and pressure sensations (composite) | 22% / 7% | Includes chest, neck, throat, jaw; strongly dose-related |
| Neurological events (composite) | 21% / 10% | Includes dizziness, somnolence, vertigo |
| Atypical sensations (composite) | 18% / 6% | Includes paresthesia and warm/cold sensations |
| Digestive events (composite) | 14% / 8% | Includes nausea, dry mouth, dyspepsia, dysphagia |
| Adverse Effect | 1 mg / 2.5 mg / 5 mg / Placebo | Clinical Note |
|---|---|---|
| Neck/throat/jaw pain/tightness/pressure | 4% / 7% / 10% / 3% | Most frequently reported triptan-class effect; dose-related |
| Dizziness | 6% / 8% / 10% / 4% | Dose-related; advise against driving |
| Paresthesia | 5% / 7% / 9% / 2% | Tingling in extremities and face; strongly dose-related |
| Asthenia | 5% / 3% / 9% / 3% | Variable dose-response pattern |
| Somnolence | 5% / 6% / 8% / 3% | Dose-related; usually transient |
| Warm/cold sensation | 6% / 5% / 7% / 4% | Brief; typically self-limiting |
| Nausea | 4% / 9% / 6% / 4% | Peak at 2.5 mg; may overlap with migraine nausea |
| Chest pain/tightness/pressure/heaviness | 2% / 3% / 4% / 1% | Non-ischemic in most patients; evaluate if CV risk present |
| Heaviness (other than chest or neck) | 1% / 2% / 5% / 1% | Dose-related; limb heaviness commonly described |
| Dry mouth | 5% / 3% / 3% / 2% | Highest at lowest dose paradoxically; mild |
| Sweating | 0% / 2% / 3% / 1% | Mild; dose-related |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Myocardial ischemia / infarction | Very rare | Within hours of dose | Discontinue permanently; emergency cardiac care |
| Coronary vasospasm (Prinzmetal-type) | Very rare | Minutes to hours | Discontinue permanently; cardiac monitoring |
| Cardiac arrhythmias (VT/VF) | Very rare | Within hours | Emergency resuscitation; permanent discontinuation |
| Cerebrovascular events (stroke, hemorrhage) | Very rare | Variable | Discontinue immediately; neurological assessment |
| Serotonin syndrome | Rare | Minutes to hours (with serotonergic co-administration) | Discontinue all serotonergic agents; supportive care |
| Anaphylaxis / angioedema | Very rare | Any time | Emergency treatment; permanent contraindication |
| Peripheral vasospasm (GI ischemia, Raynaud syndrome) | Very rare | Hours post-dose | Discontinue; rule out vasospasm before retreatment |
| Medication overuse headache | Increases with ≥10 days/month use | Weeks to months | Withdrawal and preventive therapy transition |
Zolmitriptan has a higher incidence of neck/throat/jaw tightness than some other oral triptans (10% at 5 mg vs 3% placebo). These sensations are dose-related and almost always non-cardiac. Starting at 2.5 mg rather than 5 mg meaningfully reduces the incidence (7% vs 10%) with comparable headache relief. Proactive counselling about the expected nature and brevity of these symptoms improves adherence.
Drug Interactions
Zolmitriptan is primarily metabolized by CYP1A2, which distinguishes it from MAO-A-dependent triptans (sumatriptan, rizatriptan). This makes zolmitriptan susceptible to CYP1A2 inhibitor interactions but independent of propranolol (unlike rizatriptan, which requires dose reduction with propranolol). MAO-A inhibitors still increase exposure because MAO-A contributes to metabolism at higher doses.
Monitoring
- Cardiovascular AssessmentBefore first dose
RoutinePerform CV evaluation in triptan-naive patients with multiple risk factors. Consider first dose in medically supervised setting with ECG. - Blood PressureEach clinical visit
RoutineAt 5 mg, SBP increases ~1 mmHg and DBP ~5 mmHg in healthy subjects. In hepatic impairment, 20–80 mmHg elevations reported. Contraindicated in uncontrolled hypertension. - Headache FrequencyMonthly diary
RoutineSafety of treating >3 migraines/30 days not established. Using triptans ≥10 days/month risks medication overuse headache. - Hepatic FunctionBaseline (if indicated)
Trigger-basedModerate-severe impairment increases AUC 3-fold and causes significant BP risk. Dose reduction to 1.25 mg required. - Serotonin SyndromeEach use with serotonergic drugs
Trigger-basedWatch for agitation, hyperthermia, hyperreflexia, clonus, tremor when co-administered with SSRIs, SNRIs, TCAs, or MAO inhibitors. - Cardiac SymptomsAny new symptom
Trigger-basedEvaluate chest pain, palpitations, or dyspnea for cardiac ischemia before continued use. Most chest/pressure symptoms are non-cardiac.
Contraindications & Cautions
Absolute Contraindications
- Ischemic coronary artery disease or coronary artery vasospasm (including Prinzmetal angina)
- Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
- History of stroke, TIA, or hemiplegic or basilar migraine
- Peripheral vascular disease or ischemic bowel disease
- Uncontrolled hypertension
- Use of another triptan or ergotamine within 24 hours
- Concurrent or recent MAO-A inhibitor use (within 2 weeks)
- Known hypersensitivity to zolmitriptan (angioedema, anaphylaxis reported)
Relative Contraindications (Specialist Input Recommended)
- Multiple cardiovascular risk factors — requires CV evaluation before first dose
- Moderate-to-severe hepatic impairment — dose reduction required; significant BP risk
Use with Caution
- Concurrent SSRI/SNRI/TCA therapy — serotonin syndrome risk
- Concurrent CYP1A2 inhibitors (cimetidine, fluvoxamine, ciprofloxacin) — dose reduction may be required
- Phenylketonuria — ODT formulation contains phenylalanine (2.81 mg per 2.5 mg tablet; 5.62 mg per 5 mg tablet)
- Pregnancy — animal data suggest fetal harm; limited human data
- High-frequency use (≥10 days/month) — medication overuse headache risk
Serious cardiac events, including myocardial infarction, have occurred following 5-HT1 agonist use. Some have occurred in patients without known cardiovascular disease. Perform cardiovascular evaluation in patients with multiple risk factors before administering zolmitriptan. Consider first dose in a medically supervised setting with post-dose ECG in higher-risk patients.
Patient Counselling
Purpose of Therapy
Zolmitriptan is a rescue medication that stops a migraine attack once it has started. It works by narrowing dilated blood vessels in the brain and blocking pain signals. It should be taken as early as possible after headache onset. It does not prevent future migraines.
How to Take
Swallow the standard tablet whole with water. For the orally disintegrating tablet (ODT), place on the tongue with dry hands and let it dissolve — no water is needed. The medication can be taken with or without food. If the headache returns after initial relief, a second dose can be taken at least 2 hours later. Do not exceed 10 mg in 24 hours.
Sources
- Zolmitriptan Tablets — Full Prescribing Information. Revised February 2026. drugs.com/pro/zolmitriptanCurrent FDA-approved PI for zolmitriptan tablets; primary source for dosing, adverse reaction Table 1, contraindications, and drug interaction data.
- ZOMIG / ZOMIG-ZMT (zolmitriptan) — Full Prescribing Information. AstraZeneca. FDA Label (PDF)Brand-name PI with detailed PK parameters, hepatic impairment data, and blood pressure findings.
- ZOMIG Nasal Spray (zolmitriptan) — Full Prescribing Information. FDA Label (PDF)Nasal spray PI with adolescent dosing data and nasal-spray-specific adverse reactions.
- Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig) for the acute treatment of migraine: a multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology. 1997;49(5):1210-1218. doi:10.1212/WNL.49.5.1210Pivotal dose-ranging RCT establishing that 2.5 mg and 5 mg are more effective than 1 mg, with 5 mg offering little added benefit over 2.5 mg.
- Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia. 2002;22(2):101-106. doi:10.1046/j.1468-2982.2002.00327.xEfficacy trial for the ODT formulation demonstrating comparable efficacy to the conventional tablet with added convenience.
- Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi:10.1111/head.12499AHS evidence assessment establishing Level A evidence for oral zolmitriptan in acute migraine treatment.
- Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633-658. doi:10.1046/j.1468-2982.2002.00404.xDefinitive meta-analysis comparing all triptans; positions zolmitriptan 2.5 mg as having a favorable efficacy-to-tolerability ratio.
- Martin GR. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997;17(Suppl 18):4-14. doi:10.1177/0333102497017S1802Foundational preclinical review demonstrating zolmitriptan’s dual peripheral and central mechanisms of action, including CNS penetration.
- Goadsby PJ, Lipton RB, Ferrari MD. Migraine — current understanding and treatment. N Engl J Med. 2002;346(4):257-270. doi:10.1056/NEJMra010917Landmark review of migraine pathophysiology and the role of CGRP inhibition by triptans.
- Dixon R, Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia. 1997;17(Suppl 18):15-20. doi:10.1177/0333102497017S1803Comprehensive PK review establishing key parameters: bioavailability ~40%, t½ ~3 h, protein binding ~25%, CYP1A2 metabolism.
- Dixon R, French S, Kemp J, Sellers M, Yates R. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin Drug Investig. 1998;15(6):515-522. doi:10.2165/00044011-199815060-00008Key drug interaction study quantifying the effect of cimetidine (CYP1A2 inhibitor) and rifampicin (CYP inducer) on zolmitriptan PK.
- Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: a review of its use in migraine. Drugs. 1999;58(2):347-374. doi:10.2165/00003495-199958020-00016Comprehensive clinical review covering pharmacology, efficacy, tolerability, and the role of the active N-desmethyl metabolite.
- Kalanuria AA, Peterlin BL. A review of the pharmacokinetics, pharmacodynamics and efficacy of zolmitriptan in the acute abortive treatment of migraine. Clin Med Ther. 2009;1:1353-1366. doi:10.4137/CMT.S2056Detailed review of zolmitriptan PK including gender differences, hepatic impairment data, and ictal vs interictal absorption differences.